Cancer Drugs Fast-Tracked by the FDA in May 2025
In May 2025, the U.S. Food and Drug Administration (FDA) granted fast track designations to several key oncology drugs for cervical, blood, and lung cancers, among others. ISB 2001 for Relapsed/Refractory Multiple Myeloma On May 5, Ichnos Glenmark Innovation announced that the FDA granted fast track designation to ISB 2001, an investigational trispecific antibody, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. “Our trispecific candidate is designed to enhance tumor targeting while reducing on-target, off-tumor toxicity,” said Cyril Konto, MD, CEO and president of IGI, in a news release. ISB 2001 was well-tolerated with manageable toxicities and demonstrated robust antimyeloma activity in heavily pretreated patients, according to data presented at the 2025 American Society of Cli...